videx 25mg chewable dispersible tablets
bristol-myers squibb pharmaceuticals ltd - didanosine - chewable tablet - 25mg
sprycel 20mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 20mg
sprycel 50mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 50mg
sprycel 100mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 100mg
sprycel 140mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 140mg
sprycel 80mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 80mg
videx ec
bristol-myers squibb australia pty ltd - didanosine -
capozide 25mg/50mg tablets
bristol-myers squibb pharmaceuticals ltd - hydrochlorothiazide; captopril - oral tablet - 25mg ; 50mg
reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - other antianemic preparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1).
reblozyl 25 mg
bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 25 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia